NICB

Research Interests:

Drug resistance in cancer, platinum and taxane chemotherapy.

Selected Peer Reviewed Journals

• Dr Britta Stordal. .
• Stordal, B and Davey R. 2009. ERCC1 expression and RAD51B activity correlate with cell cycle response to platinum drug treatment not DNA repair. Cancer Chemotherapy And Pharmacology, 63, 4, pp661-672.
• Stordal, B and Davey R. 2009. A systematic review of genes involved in the inverse resistance relationship between cisplatin and paclitaxel chemotherapy: Role of BRCA1. Current Cancer Drug Targets, 9, 3, pp354-365.
• Stordal, B. and Davey R. 2008. A 39kDa fragment of endogenous ASK1 suggests specific cleavage not degradation by the proteasome. Iubmb Life, 60, 3, pp180-184.
• Stordal, B. and Davey, M. 2007. Understanding cisplatin resistance using cellular models. Iubmb Life, 59, 11, pp696-699.
• Stordal, B., Pavlakis, N. and Davey, R. 2007. Oxaliplatin for the treatment of cisplatin-resistant cancer: A systematic review. Cancer Treatment Reviews, 33, 4, pp347-357.
• Stordal, B., Pavlakis, N. and Davey, R. 2007. A systematic review of platinum and taxane resitance from bench to clinic: An inverse relationship. Cancer Treatment Reviews, 33, , pp688-703.
• Stordal, B., Davey, M. and Davey, R. 2006. Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells. Cancer Chemotherapy And Pharmacology, 58, 2, pp256-265.
• Stordal, B., Peters, G. and Davey, R. 2006. Similar chromosomal changes in cisplatin-resistant and oxaliplatin-resistant sublines of the H69 SCLC cell line are not associated with platinum resistance. Genes, Chromosones & Cancer, 45, 12, pp1094-1105.

Selected Chapters

• Stordal, B and Davey, R. 2009. SYSTEMATIC ANALYSIS OF PATTERNS OF CROSS RESISTANCE BETWEEN ANTICANCER AGENTS. Drug Resistant Neoplasms
• Stordal, B. and Davey, R. 2009. Regrowth resistance: Low-level platinum resistance mediated by rapid recovery from platinum-induced cell cycle arrest. Platinum and Other Heavy Metal Compounds in Cancer Chemotherapy.
• Stordal, B., Pavlakis, N. and Davey, R. 2009. Treating cisplatin-resistant cancer: A systematic analysis of oxaliplatin or paclitaxel salvage chemotherapy. Platinum and Other Heavy Metal Compounds in Cancer Chemotherapy.

• , , , - ,
• Stordal, B, Pavlakis, N. and Davey, R., Treating cisplatin-resistant ovarian cancer: oxaliplatin or paclitaxel salvage chemotherapy and potential markers of resistance., In: Current Treatment Options in Oncology ed.Chemotherapy Foundation Symposium, 05-NOV-08 - 07-NOV-08, New York, NY, USA
• Stordal, B, Pavlakis, N. and Davey, R, The inverse relationship between cisplatin and paclitaxel resistance: Two magic bullets are needed., 2nd World Conference on Magic Bullets (Ehrlich II), 03-OCT-08 - 05-OCT-08, Nuremburg, Germany
• Stordal, B. and Davey, R., Regrowth resistance: Low-level platinum resistance mediated by rapid recovery from platinum-induced cell cycle arrest., 10th International Symposium on Platinum Coordination Compounds in Cancer Chemotherapy., 30-NOV-07 - 03-DEC-07, Verona, Italy
• Stordal, B., Pavlakis, N. and Davey, R., Treating cisplatin-resistant cancer: A systematic analysis of oxaliplatin or paclitaxel salvage chemotherapy., 10th International Symposium on Platinum Coordination Compounds in Cancer Chemotherapy., 30-NOV-07 - 03-DEC-07, Verona, Italy
• Stordal, B., New perspectives on platinum resistance in cancer., University of Sydney - Cancer Research Network Mini-Symposium - Cancer Therapeutics: Drug design, resistance and treatment., 06-SEP-07 - 06-SEP-07, Sydney, Australia.
• Stordal, B., Peters G., St Heaps, L. and Davey, R., Oxaliplatin and cisplatin cause similar chromosomal changes in H69 SCLC cells: Linking changes in genotype to the resistant phenotype., American Association for Cancer Research, 01-APR-06 - 05-APR-06, Washington DC, USA
• Stordal, B., Davey, M. and Davey, R, Oxaliplatin does not have activity against low-level cisplatin resistance in a lung cancer cell model., American Association for Cancer Research, 16-APR-05 - 21-APR-05, Anaheim CA, USA